Skip to main content
OpenTrials
Completed

NCT Number: NCT03087552

Mini-invasive Balloon Aortic Valvuloplasty

The spreading of transcatheter aortic valve implantation has paradoxically increased the spectrum of indications for balloon aortic valvuloplasty. Balloon aortic valvuloplasty is currently used as destination therapy for patients excluded from transcatheter aortic valve implantation, as bridge to transcatheter aortic valve implantation or to surgical aortic valve replacement, or as a stratification tool for selected high-risk patients who cannot be immediate candidates for transcatheter aortic valve implantation. Moreover, it has been recently showed that transcatheter aortic valve implantation without balloon aortic valvuloplasty is encumbered by an increased risk of cerebral embolization. However, balloon aortic valvuloplasty has a complication rate comparable to transcatheter aortic valve implantation, mainly related to access site or temporary pacemaker implantation. Thus, a transradial mini-invasive approach with rapid pacing through the 0,035 inch left ventricular support wire could be extremely appealing.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital of Ferrara, Cona, Ferrara, Italy

Loading trial locations.

About this study

Consecutive patients with severe aortic stenosis with indication to aortic balloon valvuloplasty will be enrolled. An ad hoc informed consent for the procedure will be obtained from all patients.

This is a prospective observational study. The Investigators will include patients where aortic ballloon valvuloplasty is attempted by radial access and without temporary pacemaker implantation. The aim is to register and monitor the effectiveness and safety of this approach. Details regarding management of radial access and pacing with 0.035 wire can be found in the references reported below. The primary endpoint will be the 30-day occurence of minor and major vascular complications according VARC 2 classification. The safety endpoint will be the absence of intra- or periprocedural major complications in transradial balloon aortic valvuloplasty, namely balloon entrapment or compartment syndrome requiring surgical intervention.

The feasibility endpoint will be a procedural success rate ≥90%. The efficacy endpoint will be a reduction of the mean invasive gradient >30%. At baseline, Handgrip strength test will be performed and angiography of the instrumented arm will be performed at the beginning and at the end of the procedure. All patients will be prospectively followed-up for at least 30 days and all adverse events will be recorded. All patients will be assessed also for frailty according the clinical frailty scale (CFS). During the 30-day follow-up visit two independent blinded operators will evaluate radial artery patency by ultrasonography and perform handgrip strength test in in both arms in all patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • severe symptomatic aortic stenosis requiring balloon aortic valvuloplasty

Exclusion criteria

  • cardiogenic shock
  • bilateral absence of radial pulse

Treatment and study plan

Transradial balloon aortic valvuloplasty

Procedure

Mini-invasive balloon aortic valvuloplasty consisting in transradial access

Primary outcomes

  1. Vascular complications

    Time frame: 1 month

    Cumulative occurrence of major and minor bleeding complications according the VARC-2 classification

Secondary outcomes

  1. Transradial balloon aortic valvuloplasty major complications

    Time frame: 1 month

    Balloon entrapment, compartment syndrome requiring surgical intervention

  2. Adverse events

    Time frame: 1 month

    Cumulative occurrence of death, stroke, coronary occlusion, coronary dissection, moderate-severe aortic regurgitation, severe hypotension requiring intervention, pericardiocentesis, definitive pace-maker implantation

  3. Major vascular complications

    Time frame: 1 month

    Cumulative occurrence of major bleeding complications according the VARC-2

  4. Minor vascular complications

    Time frame: 1 month

    Cumulative occurrence of minor bleeding complications according the VARC-2

  5. Radial artery occlusion

    Time frame: 1 month

    Cumulative occurrence of radial artery occlusion

  6. Radial artery occlusion

    Time frame: 24 hours

    Cumulative occurrence of radial artery occlusion

Other outcomes

  1. Frailty assessment

    Time frame: 1 month

    Improvement from baseline to 1 month of the Clinical Frailty Scale. The Clinical Frailty Scale (CFS) ranges from 1 to 9, with higher values suggestive for poor prognosis

  2. Physical performance assessment

    Time frame: 1 month

    Improvement from baseline to 1 month of grip strength

  3. Essential Frailty Toolset

    Time frame: 1 month

    Improvement from baseline to 1 month of the value of the Essential Frailty Toolset scale. The Essential Frailty Toolset (EFT) ranges from 0 to 5, with higher values suggestive for poor prognosis

Sponsors and collaborators

Lead sponsor

University Hospital of Ferrara

Other

Registry information

Official study title

Safety and Feasibility of Transradial Mini-invasive Balloon Aortic Valvuloplasty

Acronym: SOFTLY-II

Important dates

Study start
2017
Primary completion
2020
Study completion
2021
First posted
Mar 22, 2017
Registry last updated
Apr 29, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.